Timothy Rolph, Chief Scientific Officer at Akero Therapeutics, Inc. (AKRO), sold 42,332 shares at $50.00 ($2.2M) on 2022-12-28, disclosed to the SEC on 2022-12-30.
Open-market sale of $2.2M AKRO by Chief Scientific Officer. Not flagged as scheduled, tax-driven, or recurring — but no specific bearish signal from our filters. Reasons for insider sales vary widely.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $50.00 | 1,700 | $85K | 3.9% |
| 2 | $50.55 | 8,023 | $406K | 18.8% |
| 3 | $50.55 | 8,023 | $406K | 18.8% |
| 4 | $51.38 | 12,293 | $632K | 29.3% |
| 5 | $51.38 | 12,293 | $632K | 29.3% |
| Total | $51.01 avg | 42,332 |
| $2.2M |
| 100% |
| Filing → |
| AKRO | SELL | 2025-09-10 | $1.1M | — | Filing → |
| AKRO | SELL | 2025-08-07 | $1.2M | — | Filing → |
| AKRO | SELL | 2025-07-09 | $1.2M | — | Filing → |